$3.20
0.00% yesterday
Nasdaq, Aug 12, 03:30 pm CET
ISIN
US2697961082
Symbol
EGRX

Eagle Pharmaceuticals, Inc. Stock price

$3.20
-0.54 14.44% 1M
+2.02 171.19% 6M
+2.70 540.00% YTD
-0.85 20.99% 1Y
-32.59 91.06% 3Y
-40.52 92.68% 5Y
-77.72 96.05% 10Y
-9.63 75.06% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.00 0.00%
ISIN
US2697961082
Symbol
EGRX
Industry

Key metrics

Basic
Market capitalization
$41.6m
Enterprise Value
$96.4m
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
3.5 | 0.7
P/S
0.2 | 0.2
EV/Sales
0.4 | 0.4
EV/FCF
negative
P/B
0.2
Financial Health
Equity Ratio
57.5%
Return on Equity
15.2%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | $263.5m
EBITDA
- | $82.3m
EBIT
- | $35.6m
Net Income
- | -
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -16.8%
EBITDA
- | -28.1%
EBIT
- | -65.2%
Net Income
- | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | 31.2%
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
4.2%
Employees
134
Rev per Employee
$2.4m
Show more

Is Eagle Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Eagle Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Eagle Pharmaceuticals, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Eagle Pharmaceuticals, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Eagle Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '23
+/-
%
258 258
5% 5%
100%
- Direct Costs 78 78
8% 8%
30%
180 180
10% 10%
70%
- Selling and Administrative Expenses 102 102
31% 31%
40%
- Research and Development Expense 36 36
20% 20%
14%
57 57
31% 31%
22%
- Depreciation and Amortization 21 21
356% 356%
8%
EBIT (Operating Income) EBIT 36 36
54% 54%
14%
Net Profit 12 12
47% 47%
5%

In millions USD.

Don't miss a Thing! We will send you all news about Eagle Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eagle Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
5 months ago
WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has approved an amendment to its previously disclosed limited duration stockholder rights plan (the “Rights Plan”) to increase the initial purchase price of each preferred share purchase right issued under the R...

Company Profile

Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban, ryanodex, docetaxel injection, non-alcohol formulation and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.

Head office United States
CEO Michael Graves
Employees 134
Founded 2007
Website www.eagleus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today